Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.3 USD | +31.43% | +61.56% | +148.28% |
Sales 2024 * | 1.81M 144M | Sales 2025 * | 13.23M 1.06B | Capitalization | 1.09B 87.1B |
---|---|---|---|---|---|
Net income 2024 * | -171M -13.67B | Net income 2025 * | -178M -14.23B | EV / Sales 2024 * | 363 x |
Net cash position 2024 * | 433M 34.64B | Net cash position 2025 * | 427M 34.1B | EV / Sales 2025 * | 50.1 x |
P/E ratio 2024 * |
-7.42
x | P/E ratio 2025 * |
-8.25
x | Employees | 85 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.6% |
Latest transcript on Cullinan Therapeutics, Inc.
1 day | +31.43% | ||
1 week | +61.56% | ||
Current month | +48.47% | ||
1 month | +48.47% | ||
3 months | +93.57% | ||
6 months | +200.12% | ||
Current year | +148.28% |
Managers | Title | Age | Since |
---|---|---|---|
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 17/10/21 |
Jeffrey Jones
CTO | Chief Tech/Sci/R&D Officer | 53 | 27/02/22 |
Jacquelyn Sumer
CMP | Compliance Officer | 46 | 14/08/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 31/07/17 | |
Thomas Ebeling
BRD | Director/Board Member | 65 | 31/07/17 |
Stephen Webster
BRD | Director/Board Member | 63 | 31/08/20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 25.3 | +31.43% | 4,747,718 |
25/04/24 | 19.25 | +1.91% | 1,550,075 |
24/04/24 | 18.89 | +13.32% | 1,173,778 |
23/04/24 | 16.67 | +6.65% | 966,393 |
22/04/24 | 15.63 | -0.19% | 968,160 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+148.28% | 1.09B | |
+1.51% | 42.75B | |
+48.04% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CGEM Stock